L02AE02 • leuprorelin • Antineoplastic and immunomodulating agents | Hormones and related agents | Gonadotropin releasing hormone analogues
Leuprorelin is a gonadotropin-releasing hormone (GnRH) agonist used for the treatment of prostate cancer, endometriosis, and precocious puberty. It works by suppressing the production of sex hormones, thereby reducing disease progression.
The medication is administered as a subcutaneous or intramuscular injection, usually once a month or at longer intervals, as directed by a doctor.
Side effects may include hot flashes, decreased libido, fatigue, or bone pain. In rare cases, severe allergic reactions or depression may occur.
Leuprorelin is not recommended for pregnant or breastfeeding women or patients with hypersensitivity to this medication.
Substance: leuprorelin
Date of last drug list: 01-06-2025
Commercial code: W67702007
Concentration: 22.5mg
Pharmaceutical form: powder + solvent for injection
Quantity: 1
Product type: original
Price: 826.86 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: ASTELLAS PHARMA EUROPE B.V. - OLANDA
Holder: RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A - ITALIA
Number: 12162/2019/02
Shelf life: 2 years-after packing for marketing;after reconstitution-se administreaza imediat pacientului